page 1 of 2 half year results period ended 31 december 2004 key points in line with projections net cash outflow aud 3 million balance 12 5 starpharma leads consortium to develop second generation microbicide following us 4 nih grant recognised top five nanotech breakthroughs by the forbes wolfe report reporting also secured a major deal dow chemical company and established level american depositary receipts adr facility 24 february 2005 holdings limited asx spl usotc sphry today announced its for six months ending during this achieved number significant milestones including successful application national institute health funding usd an international vaginal are at vivagel is most advanced nano based drug regulatory system was first dendrimer
